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Eﬃcacy of anti-cancer agents in clinical trials is mainly
determined on the basis of objective response rate. The
response evaluation criteria introduced by the World
Health Organization (WHO) have been reviewed, and a
new set of response criteria proposed by the Response
Evaluation Criteria in Solid Tumors (RECIST) Group.
These simplified guidelines are still based on the change
of the tumour size under treatment, but introduce the use of
unidimensional measurement, and of new methods of
assessing tumour lesions.
Introduction
Overall survival and objective response rates are the
usual parameters used to assess response to treatment in
cancer patients. Overall survival is the gold standard but
the delay necessary to obtain this parameter is too
long: physicians need to determine rapidly whether the
agent demonstrates encouraging results or not, in order
to adjust therapy. In contrast to survival, objective
response is more diﬃcult to assess because it is highly
dependent on the quality of radiological tumour
measurements. Because of the cost and toxicity of treat-
ments, a rigorous evaluation of their eﬃcacy is neces-
sary, as well as evaluation of the toxicity. Many factors
interfere with response evaluation, such as the quality
and reproducibility of the imaging examinations, the
choice of targets and the investigator’s objectivity.
International rules for measurement of therapeutic
response were progressively established during the
1970s. The WHO (World Health Organization) cri-
teria[1] published by Miller in 1981[2] have been widely
adopted and remain the standard method of reporting
tumour response to treatment. Recently, members of
the National Cancer Institute (NCI), of the National
Cancer Institute Canada (NCI Canada) and of the
European Organization for Research and Treatment of
Cancer (EORTC) have proposed a new set of tumour
response criteria (Response Evaluation Criteria in Solid
Tumours : RECIST) designed to replace existing WHO
criteria[3].
WHO criteria
Tumour size is determined by measurement of the
‘tumour area’ by multiplication of the largest diameter
of the tumour by the greatest perpendicular diameter
and, when multiple lesions are present, by the sum of
the products of the perpendicular diameters. Complete
response is defined as the disappearance of all known
disease, determined by two observations not less than 4
weeks apart. Partial response is defined as a decrease of
50% or more in the size of the lesions and progressive
disease as a 25% or more increase in the size of one or
more measurable lesions, or the appearance of new
lesions.
Reasons for response rate variability
A French group (the Research Group in Clinical
Evaluation: GREC) studied the impact of an evaluation
committee on patients’ overall response status in a large
multicentre trial in oncology[4]. It identified reasons for
disagreements between investigators and the evaluation
committee. Overall tumour responses were reduced by
23% by the review evaluation committee. Reasons for
major disagreements included errors in tumour measure-
ments, errors in selection of measurable targets. Pitfalls
such as tumour necrosis, intercurrent diseases, and
radiologic technical problems were highlighted. The
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group recommended that an independent evaluation
committee should review all therapeutic trial results.
RECIST
These new criteria support the simplification of response
evaluation through the use of unidimensional measure-
ments and the sum of the longest diameters instead of
the conventional method using two measurements and
the sum of the products.
It is important to note that the RECIST criteria still
rely on size change of lesions to make response assess-
ment. The guidelines introduce the use of computed
tomography (CT) and magnetic resonance imaging
(MRI). Technical recommendations are provided for the
use of CT, concerning the slice thickness, the use of
contrast media, image filming, etc. Ultrasound should
not be used to measure tumour lesions or as a possible
alternative to clinical measurements for superficial
palpable lesions. RECIST response criteria are linked to
the WHO criteria by the relationship between change in
diameter, product and volume. Partial response which
was defined as a 50% decrease using WHO criteria
(tumour area) becomes 30% with the new criteria (diam-
eter) and the disease progression becomes a 20% increase
(tumour diameter) instead of 25% (tumour area). This
relationship was chosen partially to allow comparison
with response rates obtained using WHO criteria,
particularly in historical trials. For the moment, the
RECIST guidelines are based on retrospective statistical
evaluation of measurements obtained in clinical trials.
Assessment of tumour response
Objective tumour shrinkage is widely used in everyday
clinical practice to estimate the benefit of anti-cancer
treatments. According to the RECIST criteria, a per-
centage change in tumour size of about 20% or 30%
from baseline is necessary to determine a progression or
a partial response while measurements on CT images
with electronic calipers provide a precision of more than
1 mm. Ultrasound examinations should not be used in
clinical trials to measure tumour regression or pro-
gression of lesions that are not superficial and palpable.
However, high frequency probes allow extremely
accurate measurements of cutaneous or sub-cutaneous
lesions closer to the histological than the clinical
measurements[5]. Cross-sectional imaging permits 3-
dimensional measurements (3-D) and 3-D image display
and each technique provides information about tumour
volume. While state-of-the-art imaging machines can
acquire such information these techniques are not yet
widely available. Furthermore, standardization and
simplification of methodology are desirable and it is not
sure that increased precision of measurement of tumour
volume is an important goal in clinical trials.
Decreasing tumour size is recognized as the major
indicator of tumour response, but other factors may
reflect the activity of anti-cancer agents. Metabolic
and physiological changes antecede size changes, some
tumours show little change in volume and may
also enlarge under treatment[6]. Modern imaging
technologies, particularly positron emission tomography
(PET)[7] allow functional assessment of tumour metab-
olism. Tumour neovascularity can be precisely assessed
using Doppler ultrasound with contrast agent, enhanced
dynamic CT and dynamic MRI[8,9]. However, these
techniques are not yet validated and cannot be widely
used for tumour response assessment in clinical trials.
Conclusion
The end-points of phase II drug trials remain objective
tumour response. Oncological radiologists must con-
tinue to describe objective changes in tumour size, using
simple, standardized international guidelines but have to
develop new tools that may provide additional indi-
cators not only reflecting changes in tumour volume, but
also demonstrating changes in tumour metabolism.
Key points
(1) Guidelines for tumour response evaluation
unidimensional measurements.
(2) Methods of assessing tumour size.
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